QQQ   423.38 (-0.58%)
AAPL   167.04 (-0.57%)
MSFT   404.33 (-1.82%)
META   501.80 (+1.54%)
GOOGL   155.97 (+0.32%)
AMZN   179.17 (-1.16%)
TSLA   149.90 (-3.57%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.38 (-0.58%)
AAPL   167.04 (-0.57%)
MSFT   404.33 (-1.82%)
META   501.80 (+1.54%)
GOOGL   155.97 (+0.32%)
AMZN   179.17 (-1.16%)
TSLA   149.90 (-3.57%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.38 (-0.58%)
AAPL   167.04 (-0.57%)
MSFT   404.33 (-1.82%)
META   501.80 (+1.54%)
GOOGL   155.97 (+0.32%)
AMZN   179.17 (-1.16%)
TSLA   149.90 (-3.57%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
QQQ   423.38 (-0.58%)
AAPL   167.04 (-0.57%)
MSFT   404.33 (-1.82%)
META   501.80 (+1.54%)
GOOGL   155.97 (+0.32%)
AMZN   179.17 (-1.16%)
TSLA   149.90 (-3.57%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
NASDAQ:IMV

IMV (IMV) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.49
$0.91
52-Week Range
N/A
Volume
44,800 shs
Average Volume
233,607 shs
Market Capitalization
$9.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMV stock logo

About IMV Stock (NASDAQ:IMV)

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

IMV Stock News Headlines

Nvidia Has a BIG Problem — Here’s Who Benefits MOST
#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'
Philippines sales up in February 2024
Nvidia Has a BIG Problem — Here’s Who Benefits MOST
#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'
Q4 2023 Horizon Technology Finance Corp Earnings Call
Don't Fall For These 12 Fried Chicken Myths
See More Headlines
Receive IMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
4/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMV
Fax
N/A
Employees
97
Year Founded
N/A

Profitability

Net Income
$-37,990,000.00
Net Margins
-11,547.42%
Pretax Margin
-11,547.42%
Return on Equity
-12,695.41%

Debt

Sales & Book Value

Annual Sales
$330,000.00
Book Value
($0.69) per share

Miscellaneous

Free Float
11,673,000
Market Cap
$9.63 million
Optionable
Optionable
Beta
0.95
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Andrew Hall
    Chief Executive Office & Director
  • Jennifer Schmitke
    Chief Operating Officer
  • Brittany Davison
    Chief Accounting Officer, Director & SVP-finance
  • Jeremy R. Graff
    Chief Scientific Officer
  • Stéphane Fiset
    Vice President-Clinical Research

IMV Stock Analysis - Frequently Asked Questions

Should I buy or sell IMV stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IMV in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" IMV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMV, but not buy additional shares or sell existing shares.
View IMV analyst ratings
or view top-rated stocks.

How were IMV's earnings last quarter?

IMV Inc. (NASDAQ:IMV) announced its quarterly earnings results on Thursday, November, 11th. The company reported ($1.30) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($1.30). The firm earned $0.04 million during the quarter. IMV had a negative trailing twelve-month return on equity of 12,695.41% and a negative net margin of 11,547.42%. During the same quarter in the previous year, the company posted ($1.00) EPS.

When did IMV's stock split?

Shares of IMV reverse split on Tuesday, December 13th 2022. The 1-10 reverse split was announced on Tuesday, December 13th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

This page (NASDAQ:IMV) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners